Capricor Therapeutics Faces Class Action as Filing Deadline Approaches
On September 28, 2026, the deadline approaches for investors affected by Capricor Therapeutics, Inc. to apply for lead plaintiff status in a class action lawsuit. The firm Kahn Swick & Foti, LLC (KSF), along with former Louisiana Attorney General Charles C. Foti, Jr., has brought this matter to attention, highlighting the potential losses suffered by investors who purchased Capricor's securities between December 17, 2025, and July 26, 2026.
The class action aims to address allegations that Capricor and its executives failed to disclose key information that could impact investments during the class period. According to the complaint, the issues came to light following a concerning briefing by the U.S. Food and Drug Administration (FDA) regarding Capricor's lead product candidate, Deramiocel. The FDA scrutinized the statistical analysis plan submitted by Capricor, indicating that changes made right before the submission process raised serious concerns about the product's approval chances.
This information led to a significant plunge in Capricor’s stock price, which dropped 64%, closing at $7.00 per share on July 27, 2026. The steep decline was accompanied by unusual trading volumes, indicating that many investors responded to the unsettling news regarding the FDA's assessment.
KSF is now urging all investors who may have experienced financial losses during the specified time frame to contact them before the deadline to learn how to proceed in potentially reclaiming their losses. Investors do not need to serve as lead plaintiffs to qualify for recovery under the possible settlement of this class action.
As the case unfolds, with specifics documented under Nkamga v. Capricor Therapeutics, Inc., et al., No. 326-cv-04385, it is crucial for interested parties to act swiftly. More information and guidance can be found through KSF’s dedicated resources, including their official website designed to help current and former investors navigate their rights and options in response to corporate malfeasance.
Kahn Swick & Foti, LLC, known for its prowess in securities litigation, has a strong track record in similar cases. As they continue to assist investors in recuperating losses due to deceptive practices, KSF’s involvement in this class action underlines the importance of accountability for public companies.
For those who wish to learn more about the specifics of this lawsuit or need assistance, KSF offers accessible contact options, including email and a toll-free hotline to ensure that investors have the support they need during this legal process. As the September 28 application deadline nears, it becomes increasingly critical for stakeholders in Capricor Therapeutics to stay informed and proactive regarding their rights as investors facing potential losses.
The class action aims to address allegations that Capricor and its executives failed to disclose key information that could impact investments during the class period. According to the complaint, the issues came to light following a concerning briefing by the U.S. Food and Drug Administration (FDA) regarding Capricor's lead product candidate, Deramiocel. The FDA scrutinized the statistical analysis plan submitted by Capricor, indicating that changes made right before the submission process raised serious concerns about the product's approval chances.
This information led to a significant plunge in Capricor’s stock price, which dropped 64%, closing at $7.00 per share on July 27, 2026. The steep decline was accompanied by unusual trading volumes, indicating that many investors responded to the unsettling news regarding the FDA's assessment.
KSF is now urging all investors who may have experienced financial losses during the specified time frame to contact them before the deadline to learn how to proceed in potentially reclaiming their losses. Investors do not need to serve as lead plaintiffs to qualify for recovery under the possible settlement of this class action.
As the case unfolds, with specifics documented under Nkamga v. Capricor Therapeutics, Inc., et al., No. 326-cv-04385, it is crucial for interested parties to act swiftly. More information and guidance can be found through KSF’s dedicated resources, including their official website designed to help current and former investors navigate their rights and options in response to corporate malfeasance.
Kahn Swick & Foti, LLC, known for its prowess in securities litigation, has a strong track record in similar cases. As they continue to assist investors in recuperating losses due to deceptive practices, KSF’s involvement in this class action underlines the importance of accountability for public companies.
For those who wish to learn more about the specifics of this lawsuit or need assistance, KSF offers accessible contact options, including email and a toll-free hotline to ensure that investors have the support they need during this legal process. As the September 28 application deadline nears, it becomes increasingly critical for stakeholders in Capricor Therapeutics to stay informed and proactive regarding their rights as investors facing potential losses.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.